Assessing the eventual publication of clinical trial abstracts submitted to a large annual oncology meeting

Oncologist

Volumn 21, Issue 3, 2016, Pages 261-268

  Massey, Paul R ^a   Wang, Ruibin ^b   Prasad, Vinay ^c   Bates, Susan E ^c   Fojo, Tito ^c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ClinicalTrials.gov; Oncology clinical trials; Publication rates

Indexed keywords

ANNUAL ONCOLOGY MEETING; ARTICLE; BREAST CANCER; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CONSENSUS DEVELOPMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG CANCER; NORTH AMERICAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PUBLICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; MEDICAL SOCIETY; NEOPLASMS; ONCOLOGY; PUBLISHING; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PUBLICATIONS; PUBLISHING; SOCIETIES, MEDICAL;

EID: 84960474051     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0516     Document Type: Article

References (43)

1. Jones CW, Handler L, Crowell KE et al. Nonpublication of large randomized clinical trials: Cross sectional analysis. BMJ 2013;347:f6104.
2. Riveros C, Dechartres A, Perrodeau E et al. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. PLoS Med 2013;10:e1001566; discussion e1001566.
3. Ross JS, Mulvey GK, Hines EM et al. Trial publication after registration in ClinicalTrials.Gov: A cross-sectional analysis. PLoS Med 2009;6: e1000144.
4. Misakian AL, Bero LA. Publication bias and research on passive smoking: Comparison of published and unpublished studies. JAMA 1998; 280:250–253.
5. Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 1992;267:374–378.
6. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998;279: 281–286.
7. Krzyzanowska MK. Off-label use ofcancer drugs: A benchmark is established. J Clin Oncol 2013;31: 1125–1127.
8. De Bellefeuille C, Morrison CA, Tannock IF. The fate of abstracts submitted to a cancer meeting: Factors which influence presentation and subsequent publication. Ann Oncol 1992;3:187–191.
9. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA 2003;290:495–501.
10. Hoeg RT, Lee JA, Mathiason MA et al. Publication outcomes of phase II oncology clinical trials. Am J Clin Oncol 2009;32:253–257.
11. Camacho LH, Bacik J, Cheung A et al. Presentation and subsequent publication rates of phase I oncology clinical trials. Cancer 2005;104: 1497–1504.
12. Easterbrook PJ, Berlin JA, Gopalan R et al. Publication bias in clinical research. Lancet 1991; 337:867–872.
13. Ahmed I, Sutton AJ, Riley RD. Assessment of publication bias, selection bias,andunavailable data in meta-analyses using individual participant data:A database survey. BMJ 2012;344:d7762.
14. Dickersin K, Chan S, Chalmers TC et al. Publication bias and clinical trials. Control Clin Trials 1987;8:343–353.
15. von Elm E, Röllin A, Blümle A et al. Publication and non-publication of clinical trials: longitudinal study of applications submitted to a research ethics committee. Swiss Med Wkly 2008;138:197–203.
16. Lee K, Bacchetti P, Sim I. Publication of clinical trials supporting successfulnewdrugapplications:A literature analysis. PLoS Med 2008;5:e191.
17. Chapman SJ, Shelton B, Mahmood H et al. Discontinuation and non-publication of surgical randomised controlled trials: Observational study. BMJ 2014;349:g6870.
18. Kasenda B, von Elm E, You J et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA 2014;311:1045–1051.
19. Anderson ML, Chiswell K, Peterson ED et al. Compliance with results reporting at ClinicalTrials. gov. N Engl J Med 2015;372:1031–1039.
20. Saito H, Gill CJ. How frequently do the results from completed US clinical trials enter the public domain?—A statistical analysis of the ClinicalTrials. gov database. PLoS One 2014;9:e101826.
21. FDAAA 801 Requirements. Available at https://clinicaltrials.gov/ct2/manage-recs/fdaaa.
22. Tam VC, Hotte SJ. Consistency of phase III clinical trial abstracts presented at an annual meeting of the American Society of Clinical Oncology compared with their subsequent fulltext publications. J Clin Oncol 2008;26:2205–2211.
23. Tam VC, Tannock IF, Massey C et al. Compendium of unpublished phase III trials in oncology: Characteristics and impact on clinical practice. J Clin Oncol 2011;29:3133–3139.
24. Manzoli L, Flacco ME, D’Addario M et al. Nonpublication and delayed publication of randomized trials on vaccines: Survey. BMJ 2014;348:g3058.
25. Ross JS, Mocanu M, Lampropulos JF et al.Time to publication among completed clinical trials. JAMA Intern Med 2013;173:825–828.
26. Jones N. Half of US clinical trials go unpublished. Nature 10.1038/nature.2013.14286.
27. Rosenthal R, Kasenda B, Dell-Kuster S et al. Completion and publication rates of randomized controlled trials in surgery: An empirical study. Ann Surg 2015;262:68–73.
28. Prenner JL, Driscoll SJ, FineHF et al. Publication rates of registered clinical trials in macular degeneration. Retina 2011;31:401–404.
29. Decullier E, Chan AW, Chapuis F. Inadequate dissemination of phase I trials: A retrospective cohort study. PLoS Med 2009;6:e1000034.
30. Lexchin J, Bero LA, Djulbegovic B et al. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ 2003; 326:1167–1170.
31. Bekelman JE, Li Y, Gross CP. Scope andimpact of financial conflicts of interest in biomedical research: S systematic review. JAMA 2003;289:454–465.
32. Glick N, MacDonald I, Knoll G et al. Factors associated with publication following presentation at a transplantation meeting. AmJ Transplant 2006; 6:552–556.
33. Barnes DE, Bero LA. Why review articles on the health effects of passive smoking reach different conclusions. JAMA 1998;279:1566–1570.
34. Lundh A, Sismondo S, Lexchin J et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012;12:MR000033.
35. Hopewell S, Loudon K, Clarke MJ et al. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev 2009:MR000006.
36. Boutron I, Dutton S, Ravaud P et al. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010;303:2058–2064.
37. Vera-Badillo FE, Shapiro R, Ocana A et al. Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol 2013;24:1238–1244.
38. Fassnacht M, Berruti A, Baudin E et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study. Lancet Oncol 2015;16:426–435.
39. Blay JY, Pápai Z, Tolcher AW et al. Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: A randomised, double-blind, placebocontrolled, phase 3 trial. Lancet Oncol 2015;16: 531–540.
40. Krzyzanowska MK, Pintilie M, Brezden-Masley C et al. Quality of abstracts describing randomized trials in the proceedings of American Society of Clinical Oncology meetings: Guidelines for improved reporting. J Clin Oncol 2004;22: 1993–1999.
41. Hopewell S, Clarke M. Abstracts presented at the American Society of Clinical Oncology conference: Howcompletely are trials reported? Clin Trials 2005;2:265–268.
42. Hudson KL, Collins FS. Sharing and reporting the results of clinical trials. JAMA 2015;313: 355–356.
43. Vale RD. Accelerating scientific publication in biology. Proc Natl Acad Sci USA 2015;112: 13439–13446.